Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8283)
All Articles published online
|
Publishing Process of This Article
|
Oct 28, 2016 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977 [PMID: 27833388 DOI: 10.3748/wjg.v22.i40.8967] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i40/8967.htm |
| Number | Citing Articles |
| 1 |
Yaling Hui, Ting Tang, Jing Wang, Huanhuan Zhao, Hong-Ying Yang, Junmin Xi, Baoxin Zhang, Jianguo Fang, Kun Gao, Yueting Wu. Fusaricide is a Novel Iron Chelator that Induces Apoptosis through Activating Caspase-3. Journal of Natural Products 2021; 84(8): 2094 doi: 10.1021/acs.jnatprod.0c01322
|
| 2 |
Joshua P. Gray, Natalia Suhali-Amacher, Sidhartha D. Ray. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Side Effects of Drugs Annual 2017; 39: 197 doi: 10.1016/bs.seda.2017.07.001
|
| 3 |
Man Theerasilp, Punlop Chalermpanapun, Kanyawan Ponlamuangdee, Dusita Sukvanitvichai, Norased Nasongkla. Imidazole-modified deferasirox encapsulated polymeric micelles as pH-responsive iron-chelating nanocarrier for cancer chemotherapy. RSC Advances 2017; 7(18): 11158 doi: 10.1039/C6RA26669J
|
| 4 |
Francesca Fontana, Alison K. Esser, Christopher Egbulefu, Partha Karmakar, Xinming Su, John S. Allen, Yalin Xu, Jennifer L. Davis, Ariel Gabay, Jingyu Xiang, Kristin A. Kwakwa, Brad Manion, Suzanne Bakewell, Shunqiang Li, Haeseong Park, Gregory M. Lanza, Samuel Achilefu, Katherine N. Weilbaecher, Kostas Pantopoulos. Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting. PLOS ONE 2023; 18(12): e0293700 doi: 10.1371/journal.pone.0293700
|
| 5 |
Bilal Rah, Nada Mazen Farhat, Mawieh Hamad, Jibran Sualeh Muhammad. JAK/STAT signaling and cellular iron metabolism in hepatocellular carcinoma: therapeutic implications. Clinical and Experimental Medicine 2023; 23(7): 3147 doi: 10.1007/s10238-023-01047-8
|
| 6 |
Yukimasa Makita, Shumpei Murata, Yoshiki Katou, Kuniko Kikuchi, Hiroshi Uejima, Mika Teratani, Yasutaka Hoashi, Eriya Kenjo, Satoru Matsumoto, Masahiro Nogami, Kentaro Otake, Yuji Kawamata. Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2017; 493(1): 800 doi: 10.1016/j.bbrc.2017.08.088
|
| 7 |
Sai Krishna Athuluri‐Divakar, Yujin Hoshida. Generic chemoprevention of hepatocellular carcinoma. Annals of the New York Academy of Sciences 2019; 1440(1): 23 doi: 10.1111/nyas.13971
|
| 8 |
Azmi Khan, Pratika Singh, Amrita Srivastava. Iron: Key player in cancer and cell cycle?. Journal of Trace Elements in Medicine and Biology 2020; 62: 126582 doi: 10.1016/j.jtemb.2020.126582
|
| 9 |
Mindy M. Hugo, Ipsita A. Banerjee. Development of new amphiphilic bio-organic assemblies for potential applications in iron-binding and targeting tumor cells. Soft Materials 2019; 17(1): 57 doi: 10.1080/1539445X.2018.1548357
|
| 10 |
Wataru Jomen, Takaaki Ohtake, Takayuki Akita, Daisuke Suto, Hideki Yagi, Yosuke Osawa, Yutaka Kohgo. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths. Biomedicine & Pharmacotherapy 2022; 153: 113363 doi: 10.1016/j.biopha.2022.113363
|
| 11 |
Elias Kouroumalis, Ioannis Tsomidis, Argyro Voumvouraki. Iron as a therapeutic target in chronic liver disease. World Journal of Gastroenterology 2023; 29(4): 616-655 doi: 10.3748/wjg.v29.i4.616
|
| 12 |
Hongliang You, Dao Wang, Linlin Wei, Jiao Chen, Huanhuan Li, Yufeng Liu, Yongzhong Hou. Deferoxamine Inhibits Acute Lymphoblastic Leukemia Progression through Repression of ROS/HIF-1α, Wnt/β-Catenin, and p38MAPK/ERK Pathways. Journal of Oncology 2022; 2022: 1 doi: 10.1155/2022/8281267
|
| 13 |
Wenqian Wang, Kouichi Tabu, Alapati Aimaitijiang, Tetsuya Taga. Therapy-resistant nature of cancer stem cells in view of iron metabolism. Inflammation and Regeneration 2022; 42(1) doi: 10.1186/s41232-022-00220-y
|
| 14 |
Christopher J. Greene, Kristopher Attwood, Nitika J. Sharma, Kenneth W. Gross, Gary J. Smith, Bo Xu, Eric C. Kauffman. Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients. Oncotarget 2017; 8(63): 107052 doi: 10.18632/oncotarget.22323
|
| 15 |
Valentina Pita-Grisanti, Kaylin Chasser, Trevor Sobol, Zobeida Cruz-Monserrate. Understanding the Potential and Risk of Bacterial Siderophores in Cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.867271
|
| 16 |
Ola Ibrahim, Jeff O’Sullivan. Iron chelators in cancer therapy. BioMetals 2020; 33(4-5): 201 doi: 10.1007/s10534-020-00243-3
|
| 17 |
Shogo Amano, Seiji Kaino, Shuhei Shinoda, Hirofumi Harima, Toshihiko Matsumoto, Koichi Fujisawa, Taro Takami, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida. RETRACTED ARTICLE: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07167-8
|
| 18 |
Takahiro Yamasaki, Issei Saeki, Yurika Kotoh-Yamauchi, Ryo Sasaki, Norikazu Tanabe, Takashi Oono, Takashi Matsuda, Takuro Hisanaga, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Yutaka Suehiro, Isao Sakaida. Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma. Applied Sciences 2021; 11(4): 1882 doi: 10.3390/app11041882
|
| 19 |
Nan Zhou, Yan Cui, Rui Zhu, Yuhuan Kuang, Wenhui Ma, Jianyuan Hou, Yumeng Zhu, Shubo Chen, Xin Xu, Ke Tan, Pengxiu Cao, Xianglin Duan, Yumei Fan. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo. Gynecologic Oncology 2022; 166(1): 126 doi: 10.1016/j.ygyno.2022.05.006
|
| 20 |
Hui Wang, Danfeng Lin, Qianqian Yu, Zhouqi Li, Cameron Lenahan, Ying Dong, Qichun Wei, Anwen Shao. A Promising Future of Ferroptosis in Tumor Therapy. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.629150
|
| 21 |
Wojciech Szlasa, Martyna Gachowska, Karolina Kiszka, Katarzyna Rakoczy, Aleksander Kiełbik, Kamila Wala, Julia Puchała, Katarzyna Chorążykiewicz, Jolanta Saczko, Julita Kulbacka. Iron chelates in the anticancer therapy. Chemical Papers 2022; 76(3): 1285 doi: 10.1007/s11696-021-02001-2
|
| 22 |
Johanna M. Buschhaus, Shrila Rajendran, Brock A. Humphries, Alyssa C. Cutter, Ayşe J. Muñiz, Nicholas G. Ciavattone, Alexander M. Buschhaus, Tatiana Cañeque, Zeribe C. Nwosu, Debashis Sahoo, Avinash S. Bevoor, Yatrik M. Shah, Costas A. Lyssiotis, Pradipta Ghosh, Max S. Wicha, Raphaël Rodriguez, Gary D. Luker. Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer. Oncogene 2022; 41(29): 3705 doi: 10.1038/s41388-022-02385-9
|
| 23 |
A review on therapeutic use of iron in cancer treatment. 14TH INTERNATIONAL CONFERENCE ON MATERIALS PROCESSING AND CHARACTERIZATION 2023 2024; 3007: 030015 doi: 10.1063/5.0193565
|
| 24 |
Jiaqi Qin, Ce Zhou, Mengqi Zhu, Shurui Shi, Lianyun Zhang, Yanhong Zhao, Changyi Li, Yinsong Wang, Yue Wang. Iron chelation promotes 5-aminolaevulinic acid-based photodynamic therapy against oral tongue squamous cell carcinoma. Photodiagnosis and Photodynamic Therapy 2020; 31: 101907 doi: 10.1016/j.pdpdt.2020.101907
|
| 25 |
Shuhei Shinoda, Seiji Kaino, Shogo Amano, Hirofumi Harima, Toshihiko Matsumoto, Koichi Fujisawa, Taro Takami, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growthin vitroandin vivo. Oncotarget 2018; 9(47): 28434 doi: 10.18632/oncotarget.25421
|
| 26 |
Koichi Fujisawa, Taro Takami, Toshihiko Matsumoto, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida. An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells. Cancer & Metabolism 2022; 10(1) doi: 10.1186/s40170-022-00284-x
|
| 27 |
Hadis Veisi, Jaleh Varshosaz, Mahboubeh Rostami, Mina Mirian. Thermosensitive TMPO-oxidized lignocellulose/cationic agarose hydrogel loaded with deferasirox nanoparticles for photothermal therapy in melanoma. International Journal of Biological Macromolecules 2023; 238: 124126 doi: 10.1016/j.ijbiomac.2023.124126
|
| 28 |
Katie M Troike, Sabrina Z Wang, Daniel J Silver, Juyeun Lee, Erin E Mulkearns-Hubert, Nicole Hajdari, Prabar K Ghosh, Kristen E Kay, Julia L Beilis, Sofia E Mitchell, Christopher W Bishop, Ellen S Hong, Mykyta Artomov, Christopher G Hubert, Prajwal Rajappa, James R Connor, Paul L Fox, Bjarne W Kristensen, Justin D Lathia. Homeostatic iron regulatory protein drives glioblastoma growth via tumor cell-intrinsic and sex-specific responses. Neuro-Oncology Advances 2024; 6(1) doi: 10.1093/noajnl/vdad154
|
| 29 |
Axel Steinbrueck, Adam C. Sedgwick, Hai-Hao Han, Michael Y. Zhao, Sajal Sen, Dan-Ying Huang, Yi Zang, Jia Li, Xiao-Peng He, Jonathan L. Sessler. In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics. Chemical Communications 2021; 57(46): 5678 doi: 10.1039/D0CC08156F
|
| 30 |
Christopher J. Greene, Nitika J. Sharma, Peter N. Fiorica, Emily Forrester, Gary J. Smith, Kenneth W. Gross, Eric C. Kauffman. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation. Free Radical Biology and Medicine 2019; 133: 295 doi: 10.1016/j.freeradbiomed.2018.12.013
|
| 31 |
Myriam Y. Hsu, Erica Mina, Antonella Roetto, Paolo E. Porporato. Iron: An Essential Element of Cancer Metabolism. Cells 2020; 9(12): 2591 doi: 10.3390/cells9122591
|
| 32 |
Jonathan H. Joachim, Kosha J. Mehta. Hepcidin in hepatocellular carcinoma. British Journal of Cancer 2022; 127(2): 185 doi: 10.1038/s41416-022-01753-2
|
| 33 |
Toshiaki Ohara, Yasuko Tomono, Xing Boyi, Sun Yingfu, Kazuhiro Omori, Akihiro Matsukawa. A novel, nontoxic iron chelator, super-polyphenol, effectively induces apoptosis in human cancer cell lines. Oncotarget 2018; 9(67): 32751 doi: 10.18632/oncotarget.25973
|
| 34 |
Rikki A. M. Brown, Kirsty L. Richardson, Tasnuva D. Kabir, Debbie Trinder, Ruth Ganss, Peter J. Leedman. Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00476
|
| 35 |
Maura Argenziano, Alessandra Di Paola, Chiara Tortora, Daniela Di Pinto, Elvira Pota, Martina Di Martino, Silverio Perrotta, Francesca Rossi, Francesca Punzo. Effects of Iron Chelation in Osteosarcoma. Current Cancer Drug Targets 2021; 21(5): 443 doi: 10.2174/1568009620666201230090531
|
| 36 |
Erdem M. Terzi, Richard Possemato. Iron, Copper, and Selenium: Cancer's Thing for Redox Bling. Cold Spring Harbor Perspectives in Medicine 2024; 14(4): a041545 doi: 10.1101/cshperspect.a041545
|
| 37 |
Arezoo Sodagar Taleghani, Pedram Ebrahimnejad, Amir Heydarinasab, Azim Akbarzadeh. Adsorption and controlled release of iron-chelating drug from the amino-terminated PAMAM/ordered mesoporous silica hybrid materials. Journal of Drug Delivery Science and Technology 2020; 56: 101579 doi: 10.1016/j.jddst.2020.101579
|
| 38 |
Bo Li, Zhipeng Liao, Yingxi Mo, Weilin Zhao, Xiaohui Zhou, Xiling Xiao, Wanmeng Cui, Guofei Feng, Suhua Zhong, Yushan Liang, Chunping Du, Guangwu Huang, Ping Li, Xue Xiao, Xiaoying Zhou, Rensheng Wang, Zhe Zhang. Inactivation of 3-hydroxybutyrate dehydrogenase type 2 promotes proliferation and metastasis of nasopharyngeal carcinoma by iron retention. British Journal of Cancer 2020; 122(1): 102 doi: 10.1038/s41416-019-0638-8
|
| 39 |
Naoto Fujiwara, Scott L. Friedman, Nicolas Goossens, Yujin Hoshida. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. Journal of Hepatology 2018; 68(3): 526 doi: 10.1016/j.jhep.2017.09.016
|
| 40 |
Sara Ahmadi Badi, Ahmad Bereimipour, Pejman Rohani, Shohreh Khatami, Seyed Davar Siadat. Interplay between gut microbiota and the master iron regulator, hepcidin, in the pathogenesis of liver fibrosis. Pathogens and Disease 2024; 82 doi: 10.1093/femspd/ftae005
|
| 41 |
Anna Martina Battaglia, Francesco Saverio Costanzo, Flavia Biamonte. Handbook of Cancer and Immunology. 2024; : 1 doi: 10.1007/978-3-030-80962-1_374-1
|